Search Results

Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, launch a new assay for quantifying pharmacodynamic markers of radioligand therapies in tumors.

Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications announces the launch of its new multiplex spatial biology assay services for rapid, whole-slide imaging and analysis of tissue sections at subcellular resolution.

Navigate BioPharma Services, Inc. in Collaboration with Partners Validate Analytical Assay for Acute Myeloid Leukemia Measurable Residual Disease (AML-MRD) Assessment.

Navigate BioPharma Services, Inc. announces a strategic collaboration with BD (Becton, Dickinson and Company) to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their pipelines with novel and potentially more effective therapies.

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.

While layoffs slowed in the second half of 2024, biopharmas including Bayer, Bristol Myers Squibb and Johnson & Johnson cut hundreds or even thousands of employees over the course of the year.

2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024.

Rentschler Biopharma SE announced that Patrick Cushing, Ph.D., has been promoted to Vice President Operations of Rentschler Biopharma, Inc., the company’s U.S. subsidiary, effective May 1, 2024.